Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

This study has been completed.
Information provided by (Responsible Party):
Abbott Identifier:
First received: October 20, 2006
Last updated: October 14, 2011
Last verified: October 2011
The objective of this study is to compare the safety and efficacy of five doses of ABT-089 (2 mg QD, 5 mg QD, 15 mg QD, 40 mg QD and 40 mg BID) to placebo in adults with ADHD.

Condition Intervention Phase
Attention-Deficit/Hyperactivity Disorder
Drug: ABT-089
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose-Ranging Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Resource links provided by NLM:

Further study details as provided by Abbott:

Primary Outcome Measures:
  • Investigator-rated Connors' Adult ADHD Rating Scale(CAARS) total score [ Time Frame: at the final evaluation of each 4-week treatment period ]

Secondary Outcome Measures:
  • CAARS Inattentive and Hyperactive/Impulsive Sub scales Scores [ Time Frame: at the final evaluation of each 4-week treatment period ]
  • CAARS ADHD Index, CAARS:Self [ Time Frame: at the final evaluation of each 4-week treatment period ]
  • CGI-ADHD-S, AISRS, TASS, FTND [ Time Frame: at the final evaluation of each 4-week treatment period ]
  • QSU-Brief, CANTAB cognitive battery [ Time Frame: at the final evaluation of each 4-week treatment period ]

Enrollment: 221
Study Start Date: October 2006
Study Completion Date: June 2007
Primary Completion Date: June 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: 1 Drug: Placebo
Subjects will take placebo QD, BID for 4-6 weeks
Experimental: 2 Drug: ABT-089
Subjects will take 2 mg QD, 5 mg QD, 15 mg QD, 40 mg QD, 40 mg BID for 4-6 weeks


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Meet criteria for attention deficit hyperactivity disorder
  • Have voluntarily signed an informed consent form
  • Are between 18 and 60 years of age
  • Will use contraceptive methods during the study
  • Women must not be pregnant or breast-feeding
  • Must be in generally good health
  • Are fluent in English

Exclusion Criteria:

  • They have a current or past diagnosis of schizoaffective disorder, schizophrenia, obsessive-compulsive disorder, drug-induced psychosis, bipolar disorder, psychotic disorder or mental retardation
  • They have a current diagnosis of major depressive episode, generalized anxiety disorder (GAD), or post-traumatic stress disorder (PTSD) or have a clinically significant sleep disorder requiring treatment
  • They require ongoing treatment or expected treatment with any psychotropic medication, including anxiolytics, antipsychotics, anticonvulsants, antidepressants or mood stabilizers
  • They failed to respond to two or more adequate trials of FDA-approved ADHD medication
  • They have violent, homicidal or suicidal ideation
  • They have a significant history of medical diagnoses, seizure disorder, Tourette's syndrome or a central nervous system (CNS) disease, excluding ADHD
  • They have a urine drug screen that is positive for alcohol or drugs of abuse
  • They have a history of substance or alcohol disorder (abuse/dependence) during the last 3 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00391729

  Show 23 Study Locations
Sponsors and Collaborators
Study Director: Laura Gault, MD,PhD Abbott
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Abbott Identifier: NCT00391729     History of Changes
Other Study ID Numbers: M06-855
Study First Received: October 20, 2006
Last Updated: October 14, 2011

Keywords provided by Abbott:

Additional relevant MeSH terms:
Attention Deficit Disorder with Hyperactivity
Pathologic Processes
Attention Deficit and Disruptive Behavior Disorders
Neurodevelopmental Disorders
Mental Disorders
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms processed this record on May 25, 2017